New hope for aggressive thyroid cancer: drug combo trial opens
NCT ID NCT07068542
First seen Feb 28, 2026 · Last updated May 17, 2026 · Updated 6 times
Summary
This study tests two drugs—sacituzumab tirumotecan alone or with tislelizumab—in people with advanced thyroid cancer that cannot be removed by surgery or has spread. The goal is to see if these treatments can shrink tumors or help people live longer. About 94 adults with specific types of thyroid cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POORLY DIFFERENTIATED THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, Zhejiang, 310014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.